Core Insights - Alumis Inc. is set to report topline data from the Phase 3 ONWARD clinical program for envudeucitinib in patients with moderate-to-severe plaque psoriasis on January 6, 2026 [1] - A conference call and webcast will be held on the same day at 8:00 a.m. ET to discuss the results [2] Company Overview - Alumis is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company is leveraging a proprietary data analytics platform to develop a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The pipeline also includes lonigutamab for thyroid eye disease and several preclinical programs identified through a precision approach [3]
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis